| P50 | author | Arun P Lakshmanan | Q57004892 |
| P2093 | author name string | Yoshifusa Aizawa | |
| | Kenichi Watanabe | |
| | Makoto Kodama | |
| | Vivian Soetikno | |
| | Meilei Harima | |
| | Rajarajan A Thandavarayan | |
| | Vijayasree V Giridharan | |
| | Flori R Sari | |
| P2860 | cites work | Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. | Q46579574 |
| | Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? | Q46656510 |
| | Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. | Q46686146 |
| | Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. | Q46704787 |
| | The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. | Q53567620 |
| | Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice | Q57184568 |
| | A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase | Q22254730 |
| | Measurement of protein using bicinchoninic acid | Q26778491 |
| | The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 |
| | Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway | Q28571271 |
| | p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases | Q30157297 |
| | Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells | Q30164806 |
| | Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity | Q33976477 |
| | Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities | Q34009599 |
| | Angiotensin II as a mediator of tubulointerstitial injury | Q34121924 |
| | The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society | Q34292435 |
| | Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes | Q34331403 |
| | Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases | Q34468279 |
| | Diabetic nephropathy: mechanisms of renal disease progression | Q34729808 |
| | Obstructive nephropathy and renal fibrosis | Q34953429 |
| | ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy | Q35182347 |
| | Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? | Q35183933 |
| | Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells | Q36105342 |
| | p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli | Q38298446 |
| | Prevention of diabetic renal disease with special reference to microalbuminuria | Q40415958 |
| | Transforming growth factor-beta inhibition of proteasomal activity: a potential mechanism of growth arrest. | Q40662685 |
| | The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms | Q41323510 |
| | Kidney fibrosis in hypertensive rats: role of oxidative stress | Q42043098 |
| | Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney | Q42477089 |
| | Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice. | Q42939357 |
| | Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. | Q43850947 |
| | Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats | Q44042754 |
| | Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells | Q44174230 |
| | Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 |
| | Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. | Q44353743 |
| | Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment | Q44589042 |
| | Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia | Q44650457 |
| | Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. | Q44968307 |
| | A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli | Q45258260 |
| | Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice. | Q45971225 |
| | Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. | Q45997794 |
| P433 | issue | 5 | |
| P921 | main subject | renal fibrosis | Q18553516 |
| P304 | page(s) | 575-584 | |
| P577 | publication date | 2011-03-07 | |
| P1433 | published in | Free Radical Research | Q5500025 |
| P1476 | title | Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action | |
| P478 | volume | 45 | |